Roche picks up a speedy nod in Chi­na as reg­u­la­tors fol­low through on plans for a fast 48 new drug OKs

Chi­nese reg­u­la­to­ry au­thor­i­ties are fol­low­ing through with their plan to rush along a slate of new drug ap­provals. And Roche finds it­self near the front of the line formed to ben­e­fit from that new trend.

Overnight Roche re­port­ed that the Chi­na Na­tion­al Drug Ad­min­is­tra­tion had fol­lowed up with a green light for Roche to start sell­ing Ale­cen­sa as a front­line ther­a­py for ad­vanced cas­es of ALK-pos­i­tive non-small cell lung can­cer. Roche her­ald­ed an OK that ar­rived just 8 and 9 months af­ter the EMA and FDA flagged the drug through for front­line use fol­low­ing new da­ta un­der­scor­ing its ef­fi­ca­cy in treat­ing pa­tients com­pared to a stan­dard of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER